ERBB signaling and ibrutinib resistance in mantle cell lymphoma
Official title: The role of ERBB signaling in ibrutinib-resistant mantle cell lymphoma
Funded at Beckman Research Institute/city of Hope · NIH-11369418 · Data updated 2026-11-12
A short, patient-friendly look at how scientists study why some mantle cell lymphoma patients stop responding to ibrutinib and how ERBB signaling might be involved.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | June 1, 2026 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $457,683 |
| NIH project number | 1R21CA296465-01A1 |
| Project ID | NIH-11369418 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include adults with mantle cell lymphoma who have relapsed on or become resistant to BTK inhibitors like ibrutinib, or who harbor the biology described (ERBB signaling–related resistance).
✕Less likely to help
Patients whose disease does not involve ERBB-related resistance or who cannot receive targeted therapies may not benefit from these findings.
What this research studies
This project looks at why mantle cell lymphoma, a B-cell cancer, becomes resistant to the drug ibrutinib. Researchers study patient tumor samples and lab models to understand how ERBB signaling contributes to resistance and how combining ERBB-targeted drugs with existing therapies might overcome it. The team uses gene expression data and cell-line models to identify key resistance pathways and tests potential drug combinations that could extend response duration for patients. The goal is to move toward more durable treatments for people with MCL who relapse after initial therapy.
Why it matters
Potential benefit: If successful, this work could lead to new combination therapies that delay relapse and improve outcomes for patients with mantle cell lymphoma.
How similar studies have gone: Previous work has shown ERBB signaling is linked to drug resistance in B-cell cancers, with some success in combining targeted therapies in preclinical models; this study extends those findings to MCL.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Ngo, Vu Nguyen — Beckman Research Institute/city of Hope
- Study coordinator: Ngo, Vu Nguyen
Related research
Other NIH-funded projects on the same topics.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Duvelisib for preventing cytokine release syndrome in CAR T-cell therapy patients
A study tests whether taking duvelisib before CAR T-cell therapy can prevent dangerous inflammatory reactions in patients with large B-cell or mantle cell lymphoma.
-
Why some mantle cell lymphomas respond to Notch-blocking drugs
Researchers are looking at DNA regulatory changes to understand why some mantle cell lymphomas respond to drugs that block Notch while others resist them.
-
Preventing a serious side effect of CAR T-cell therapy for lymphoma
This project is testing a new medication called Duvelisib to help prevent a serious immune reaction called cytokine release syndrome in people with large cell or mantle cell lymphoma who are receiving CAR T-cell therapy.
-
Understanding CEACAM1 in Mantle Cell Lymphoma and New Treatments
This research looks for new ways to treat mantle cell lymphoma, especially for patients whose current medications are not working well.
-
Understanding how certain cancers respond to Notch inhibitors
This study is looking into why some people with mantle cell lymphoma and chronic lymphocytic leukemia benefit from Notch inhibitors while others don’t, hoping to find clues in their genes that could help create better treatments for everyone.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.